Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261531 | 1.00 | SLC6A4 (0.42) | SLC6A4GBA1IDO1TDO2CES2 | |
| SCHEMBL1727838 | 1.00 | SLC6A4 (0.42) | SLC6A4GBA1IDO1TDO2CES2 | |
| Hydrochloric Acid SCHEMBL20791551 | 0.98 | SLC6A4 (0.41) | SLC6A4GBA1IDO1TDO2CES2 | |
| Hydrochloric Acid SCHEMBL20791409 | 0.98 | SLC6A4 (0.41) | SLC6A4GBA1IDO1TDO2CES2 | |
| Hydrochloric Acid SCHEMBL3159072 | 0.98 | SLC6A4 (0.41) | SLC6A4GBA1IDO1TDO2CES2 | |
| SCHEMBL3715620 | 0.87 | SLC6A4 (0.37) | SLC6A4 | |
| SCHEMBL13075511 | 0.82 | TACR1 (0.40) | SLC6A4IDO1TDO2 | |
| SCHEMBL172564 | 0.82 | GBA1 (0.34) | GBA1IDO1TDO2CES2CES1 | |
| SCHEMBL18793763 | 0.81 | FGFR1 (0.37) | SLC6A4GBA1 | |
| SCHEMBL14383027 | 0.79 | SLC6A4 (0.41) | SLC6A4CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11987597-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-7338968-B2 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | SLC6A4 2425/4885GBA1 3059/4885IDO1 4536/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | SLC6A4 2425/4885GBA1 3059/4885IDO1 4536/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | SLC6A4 4197/4885GBA1 2883/4885IDO1 991/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | SLC6A4 1333/4885GBA1 144/4885IDO1 362/4885 |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | SLC6A4 3169/4885GBA1 3368/4885IDO1 389/4885 |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | SLC6A4 4780/4885GBA1 1362/4885IDO1 1754/4885 |
| US-11987597-B2 | Modulators of TNF-α activity | TNF, TNFRSF1A, NFKBIA | SLC6A4 4790/4885GBA1 1479/4885IDO1 1679/4885 |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | NAT1, AFF1, PNMT | SLC6A4 1394/4885GBA1 192/4885IDO1 626/4885 |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | SLC6A4 4780/4885GBA1 1362/4885IDO1 1754/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SLC6A4 2425/4885GBA1 3059/4885IDO1 4536/4885 |
| US-12338262-B2 | Modulators of TNF-alpha activity | TNF, TNFRSF1A, NFKBIA | SLC6A4 4780/4885GBA1 1362/4885IDO1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.